Rituximab as maintenance therapy for ANCA-associated vasculitides: pooled analysis and long-term outcome of 277 patients included in the MAINRITSAN trials

EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update

(2023) Bernhard Hellmich et al.   ANNALS OF THE RHEUMATIC DISEASES

Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial

(2023) Rona M Smith et al.   ANNALS OF THE RHEUMATIC DISEASES

Score to assess the probability of relapse in granulomatosis with polyangiitis and microscopic polyangiitis

(2023) Maxime Samson et al.   RMD Open

Immunogenicity of BNT162b2 vaccine against the Alpha and Delta variants in immunocompromised patients with systemic inflammatory diseases

(2022) Jerome Hadjadj et al.   ANNALS OF THE RHEUMATIC DISEASES

Association of baseline soluble immune checkpoints with the risk of relapse in PR3-ANCA vasculitis following induction of remission

(2022) Gabriele Gamerith et al.   ANNALS OF THE RHEUMATIC DISEASES

Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study

(2021) Ingrid Jyssum et al.   Lancet Rheumatology

Reducing the initial number of rituximab maintenance-therapy infusions for ANCA-associated vasculitides: randomized-trial post-hoc analysis

(2020) Pierre Charles et al.   RHEUMATOLOGY

Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab

(2020) Hendrik Schulze-Koops et al.   ANNALS OF THE RHEUMATIC DISEASES

Long-Term Rituximab Use to Maintain Remission of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

(2020) Pierre Charles et al.   ANNALS OF INTERNAL MEDICINE

How to estimate the effect of treatment duration on survival outcomes using observational data

(2018)   BMJ-British Medical Journal

How to estimate the effect of treatment duration on survival outcomes using observational data

(2018)   BMJ-British Medical Journal

Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides

(2018) Benjamin Terrier et al.   ANNALS OF THE RHEUMATIC DISEASES

Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type

(2015) Sebastian Unizony et al.   ANNALS OF THE RHEUMATIC DISEASES

Rituximab versus Azathioprine for Maintenance in ANCA-Associated Vasculitis

(2014) Loïc Guillevin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy of Remission-Induction Regimens for ANCA-Associated Vasculitis

(2013) Ulrich Specks et al.   NEW ENGLAND JOURNAL OF MEDICINE

Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients

(2012) Ronald F van Vollenhoven et al.   ANNALS OF THE RHEUMATIC DISEASES

Dynamic Regime Marginal Structural Mean Models for Estimation of Optimal Dynamic Treatment Regimes, Part I: Main Content

(2010) Liliana Orellana et al.  

Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis

(2010) John H. Stone et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis

(2010) Rachel B. Jones et al.   NEW ENGLAND JOURNAL OF MEDICINE